This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
NuVasive (NUVA) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 42.11% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for May 2nd
by Zacks Equity Research
ALEC, AMRS, and BLFS have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2022
New Strong Sell Stocks for March 31st
by Zacks Equity Research
BLFS, CRNT, and AMBA have been added to the Zacks Rank #5 (Strong Sell) List on March 31, 2022.
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -131.25% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
PETQ or BLFS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PETQ vs. BLFS: Which Stock Is the Better Value Option?
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Analysts Estimate BioLife Solutions, Inc. (BLFS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 480.00% and 10.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions, Inc. (BLFS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Medtronic (MDT) Reports Economic Findings on PRODIGY Data
by Zacks Equity Research
Medtronic (MDT)-sponsored PRODIGY Trial data was used to analyze cost benefits and outcomes from continuous pulse oximetry and capnography monitoring in high-risk patients.
Company News for May 17, 2021
by Zacks Equity Research
Companies In The News Are: ACB, NEWR, BLFS, GLOB
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 40.00% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: BioLife Solutions, Inc. (BLFS) Q1 Earnings Expected to Decline
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HRC or BLFS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRC vs. BLFS: Which Stock Is the Better Value Option?
HRC vs. BLFS: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRC vs. BLFS: Which Stock Is the Better Value Option?
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 0.00% and 9.67%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
HRC vs. BLFS: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRC vs. BLFS: Which Stock Is the Better Value Option?
HRC vs. BLFS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HRC vs. BLFS: Which Stock Is the Better Value Option?
3 Soaring MedTech Stocks That Might Lose Ground in 2021
by Trina Mukherjee
Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.
Should You Buy BioLife (BLFS) Ahead of Earnings?
by Zacks Equity Research
BioLife (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Moving Average Crossover Alert: BioLife Solutions
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
BioLife (BLFS) Catches Eye: Stock Jumps 12.1%
by Zacks Equity Research
BioLife (BLFS) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.